Review Article
Prevalence and Antimicrobial-Resistant Features of Shigella Species in East Africa from 2015–2022: A Systematic Review and Meta-Analysis
Table 2
Pooled proportions of Shigella prevalence and its drug resistance in East Africa from 2015 to 2022.
| | Antibiotics | Antibiotics resistance rates (%) reported by 22 studies | | Total (among 350 Shigellaisolates) | Countries | | Ethiopia | Kenya | Sudan | South Sudan | Somalia |
| | Tetracycline | 161 (46) | 52 (30.6) | 70 (55.1) | — | 2 (13.3) | 37 (100) | | Co- trimoxazole | 83 (23.7) | 45 (26.5) | — | — | 1 (6.7) | 37 (100) | | Ampicillin | 204 (58.3) | 109 (64.1) | 57 (44.9) | 1 (100) | 0 | 37 (100) | | Chloramphenicol | 104 (33.2) | 74 (43.5) | 29 (22.8) | — | 1 (6.7) | — | | Amoxicillin | 95 (30.4) | 95 (55.9) | 0 | — | — | — | | Gentamicin | 29 (9.3) | 25 (14.7) | — | — | 4 (26.7) | — | | Ciprofloxacin | 41 (11.7) | 19 (11.2) | 14 (11.0) | 0 | 0 | 8 (21.6) | | Norfloxacin | 5 (1.6) | 5 (2.9) | 0 | 0 | — | — | | Nalidixic acid | 25 (8.0) | 13 (7.6) | 11 (8.7) | — | 1 (6.7) | — | | Ceftriaxone | 25 (7.1) | 9 (5.3) | 0 | — | 0 | 16 (43.2) | | Overall prevalence of Shigella (350 (6.2%)) | 170 (4.0) | 127 (14.6) | 1 (0.7) | 15 (5.2) | 37 (20.6) |
|
|
Note: “—” means not done or did not get the information.
|
